Sage Therapeutics

SAGE Therapeutics is a neuroscience-focused company developing medicines to treat life-threatening, rare CNS disorders. Our mission is to make life better for patients with central nervous systems diseases by discovering, developing, and delivering important new medicines to the market. To achieve that mission we leverage compelling science, a robust clinical foundation, strong partnerships, and a world-class team of founders, advisors, investors, scientists and managers. SAGE’s lead program, SAGE-547, is in clinical development for super-refractory status epilepticus (SRSE) and is the first of many compounds the company is developing in its portfolio of potential seizure medicines. SAGE’s robust chemistry platform has generated multiple new compounds that target the GABAA and NMDA receptors, which have demonstrated preclinical activity. SAGE Therapeutics is a private company launched in 2010 by an experienced team of R&D leaders, CNS experts and investors.
Company Growth (employees)
Type
Public
HQ
Cambridge, US
Founded
2010
Size (employees)
135 (est)+118%
Website
sagerx.com
Sage Therapeutics was founded in 2010 and is headquartered in Cambridge, US

Key People at Sage Therapeutics

Jeffrey Jonas

Jeffrey Jonas

Chief Executive Officer
Kimi Iguchi

Kimi Iguchi

CFO
Stephen Kanes

Stephen Kanes

Chief Medical Officer
Albert J. Robichaud

Albert J. Robichaud

CSO
Thomas Anderson

Thomas Anderson

Chief Commercial Strategy Officer
Jim Doherty

Jim Doherty

Vice President of Pharmacology, Head of Biology

Sage Therapeutics Office Locations

Sage Therapeutics has an office in Cambridge
Cambridge, US (HQ)
215 First Street

Sage Therapeutics Metrics

Sage Therapeutics Financial Metrics

Net income (2016)

($159 m)

Market capitalization (28-Apr-2017)

$2.7 b

Closing share price (28-Apr-2017)

$71.7

Cash (31-Dec-2016)

$168.5 m
Sage Therapeutics's current market capitalization is $2.7 b.
FY, 2014FY, 2015FY, 2016

R&D expense

$24.1 m$69.4 m$120.8 m

General and administrative expense

$9.7 m$25.3 m$39.4 m

Operating expense total

$33.8 m$94.7 m$160.2 m

EBIT

($33.8 m)($94.7 m)($160.2 m)

Interest expense

$8 k

Interest income

$8 k

Net Income

($33.8 m)($94.5 m)($159 m)
FY, 2014FY, 2015FY, 2016

Cash

$127.8 m$186.8 m$168.5 m

Current Assets

$128.8 m$188.5 m$402.6 m

PP&E

$163 k$286 k$1.4 m

Total Assets

$129.7 m$189 m$404.5 m

Current Liabilities

$7.8 m$15.3 m$35.2 m

Additional Paid-in Capital

$188.7 m$335 m$689 m

Retained Earnings

($66.8 m)($161.3 m)($320.3 m)

Total Equity

$121.9 m$173.7 m$368.5 m

Financial Leverage

1.1 x1.1 x1.1 x
FY, 2014FY, 2015FY, 2016

Net Income

($33.8 m)($94.5 m)($159 m)

Depreciation and Amortization

$51 k$115 k$281 k

Accounts Payable

$228 k$140 k

Cash From Operating Activities

$119.7 m$59 m($118.7 m)

Purchases of PP&E

($128 k)($198 k)($1.4 m)

Cash From Investing Activities

($128 k)($198 k)($230.5 m)

Cash From Financing Activities

$146.9 m$129.9 m$331 m

Sage Therapeutics Market Value History

Sage Therapeutics Online Presence

Sage Therapeutics News

Sage Therapeutics Company Life

You may also be interested in